∕o,	48
70.0	ID H
MAY O B	CERTIFICATE OF MAILING
g. '	CERTIFICATE OF Multimus Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Safety Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: May 5, 2003 May 5, 2003
Mr.	by certify that this paper (along with any below with sufficient postage as inst does not be date shown below with sufficient postage as inst does not be date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as inst does not be done on the date shown below with sufficient postage as instance.
C TBA	
	Marcia Rossell Signature Type or print name

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

GORZIGLIA ET AL.

APPLICATION NO: 10/081,961

FILED: FEBRUARY 22, 2002 FOR: NOVEL VECTOR CONSTRUCTS

Commissioner for Patents Alexandria, VA 22313-1450

1653 Art Unit:

Examiner: Confirmation No. 2186

Atty. Docket 4-31890A

RECEIVED

MAY 0 8 2003 -

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Sir:

P.O. Box 1450

Enclosed please find the following:

- a. Information Disclosure Statement (1 page);
- b. PTO Form 1449 (23 pages), with cited references; and
- c. Return postcard.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Bldg. 430 East Hanover, NJ 07936-1080

Date: May 5, 2003

Douglas Golightly Patent Agent Reg. No. 51,244



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Art Unit: 1653

GORZIGLIA, et al.

Examiner:

APPLICATION NO: 10/081,961

Confirmation No. 2186

FILED: FEBRUARY 22, 2002

Attv. Docket: 4-31890A

FOR: NOVEL VECTOR CONSTRUCTS

Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Bldg. 430 East Hanover, NJ 07936-1080 (301) 258-4832

Douglas Golightly Patent Agent Reg. No. 51.244

Date: May 5, 2003

RECEIVED

TECH CENTER 1600/2900

Und the Paperwork Reductor As-

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Petent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
of 23

| Application Number | 10/081,961 | February 22, 2002 | February 22, 2002 | Fest Named Inventor | Gozziglia | Art Unit | 1653 | Examiner Name | Autorey Docket Number | 4-31890A |

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	<u> </u>	US- 10/081,969	02-22-2002	Ennist, et al.	
		US- 2001/0006633A1	07-05-2001	Kirn, D.	
	1	us- 5,672,344	09-30-1997	Kelley, et al.	
		^{US-} 5,677,178	10-14-1997	McCormick, F.	
	1	US- 5,698,443	12-16-1997	Henderson, et al.	
		us- 5,707,618	01-13-1998	Armentano, et al.	
		us- 5,830,686	11-03-1998	Henderson, D.	
		US- 5,837,511	11-17-1998	Falck-Pedersen, et a	
	1	US- 5,871,726	02-16-1999	Henderson, et al.	
		US- 5,994,128	11-30-1999	Fallaux, et al.	
		US- 5,998,205	12-07-1999	Hallenbeck, et al.	
		^{US-} 6,057,299	05-02-2000	Henderson, D.	RECE
		US- 6,136,792	10-24-2000	Henderson, D.	RECEIV
	1	US- 6,197,293B1	03-06-2001	Henderson, et al.	- 1/0
		us- 6,254,862B1	07-03-2001	Little, et al.	MAY 0 8 200
	T	us- 6,271,207B1	08-07-2001	Cristiano, et al.	Trous
		US- 6,297,219B1	10-02-2001	Nabel, et al.	TECH CENTER 1600
		US- 6,432,700B1	08-13-2002	Henderson, et al.	
		US- 6,436,394B1	08-20-2002	Henderson, et al.	

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Petent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T [‡]
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	1.
		WO 92/03563	03-05-1992			_
		WO 94/18992	09-01-1994			L
		WO 95/19434	07-20-1995			L
	1	WO 96/34969	11-07-1996			_
	1	WO 97/01358	01-16-1997			L
		WO 97/04805	02-13-1997			_

Examiner Date Considered

EXAMPLE: Initial if reference considered, whether or not clation is in conformance with MPEP 669. Draw line through clation of not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique clation designation number (optionals). See Kinds Codes of USPTO Parietto Comments at www.camboog.or of MPEP 96101.4. Extent office that issued the document, by the throatiest of Codes o

Internation is Billiorium.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or trains a beseft by the public which is to file and by the International Confidential by the Confidential by t

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent end Tredemark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 23

MECH CENTER 1600 29n Application Number 10/081,961 Filing Date February 22, 2002 First Named Inventor Gorziglia Art 1 Init 1653 Examiner Name Attorney Docket Number 4-31890A

(Use as many sheets as necessary)

Substitute for form 1449/PTO

Sheet 2

EDDS 8 O YAM

ON & TRADE

			U. S. PATEN	DOCUMENTS	Pages, Columns, Lines, Where
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	_	^{US-} 6,495,130B1	12-17-2002	Henderson, et al.	
	\vdash	US-			
	1	US-			
		US-			
		US-			
	-	US-			
	-	US-			
	-	US-			
		US-			
	 	US-			
	<u> </u>	US-			
	_	US-			
		US-			
	\vdash	US-			
	-	US-			
	1	US-			
	-	US-			
	1	US-			
	+-	US-			

		FORE	IGN PATENT DOCU	MENTS		
Exeminer Initials'	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	76
		Country Code ³ Number ⁴ Kind Code ⁶ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	1
		WO 97/48277	12-24-1997			
		WO 98/13508	04-02-1998			<u></u>
	1	WO 98/27207	06-25-1998			L
		WO 98/35028	08-13-1998			<u> </u>
		WO 98/39464	09-11-1998			_
		WO 98/39465	09-11-1998			_

Considered Signature

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). 2 See Kinds Codes of **EAAMARCH: Install released considered, whether or not casson is in contempane with nettly 800. Linear net intrope classon if not incommands and not considered, locked edge, of the flow with next communities of the contempane o

Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments **Anothing personning, programming, and assembling line complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Sheet 3

PTC/SB/08A (04-03)
Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Complete if Known						
Application Number	10/081,961	REO				
Filing Date	February 22, 2002	~C/				
First Named Inventor	Gorziglia	44.				
Art Unit	1653	may a a				
Examiner Name	TEO	8				
Attorney Docket Number	4-31890	4 Con-				
		OLIVIED 11				

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
IIIIIII	1.0.	Number-Kind Code ^{2 (Finown)}			Figures Appear		
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
	1	US-					
	_	US-					
		US-					
	\vdash	US-					
	1	US-					
	1	US-					
	1	US-					
	+-	US-					

		FORE	IGN PATENT DOCU	MENTS		-
Examiner initials*	Cite No.	e Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	70
micais	1.0.		MM-DD-YYYY		Or Relevant Figures Appear	Ľ
		WO 98/39466	09-11-1998			Ļ
	-	WO 98/39467	09-11-1998			┖
	_	WO 99/06576	02-11-1999			L
		WO 99/28469	06-10-1999			┡
	1	WO 99/55831	11-04-1999			L
	_	WO 99/59604	11-25-1999			L

Examiner Date Signature Considered

EXAMINER: I hills if mierence considered, whether or not citation is in contermance with MPEP 608. Draw in the through ricition if not in conformance and not considered include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional).* See Kinds Codes of USPTO Pearto Documents at www.usdop.cor or MPEP 6011.4.* Elene Office that issued the document, by the two-betto code (WPD). *Violend of countered by the two-betto or the place of the common content of the place of the content of the place of the common content of the place of the content of the place of the content of the place of th

This collection of information is required by 37 CFR 197 and 198. The information is required to death or retain is broad by the public which is falled to ordine the collection of the collecti

THE THAO MAN MAY 0 8 2003

Sheet 4

PTC/SB/08A (04-03) Approved for use through 04/30/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

der the Pagerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 23

MAY 8 2003
TECH CENTER 1600/2900 Application Number 10/081,961 Filing Date February 22, 2002 First Named Inventor Gorziglia 1653 Examiner Name Attorney Docket Number 4-31890

U. S. PATENT DOCUMENTS Pages, Columns, Lines, Where Publication Date Name of Patentee or Document Number Relevant Passages or Relevant Applicant of Cited Document No Figures Appear Number-Kind Code² (FAnoun) IIS. IIS. US-US-LIS US US US US US HS. US-US-US-

		FORE	IGN PATENT DOCU	MENTS		
Examiner initials*	Cite		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
11000			MM-DD-YYYY		Or Relevant Figures Appear	1
		WO 00/03029	01-20-2000			
	T-	WO 00/15820	03-23-2000			L
	1	WO 00/22124	04-20-2000			L
		WO 00/29599	05-25-2000			_
	1	WO 00/31286	06-02-2000			L
	$\overline{}$	WO 00/39319	06-06-2000			上

Considered Signature

EXAMMER: Initial If reference considered, whether or not clasion is in conformance with MPEP 609. Draw line through orizon if not in conformance and not considered, include copy of this form with next communication to applicant. *Applicant's unique citation despiration number (optional). *Ges Kinds Codes of USPTO Peared Comments is www.extgood.go. or VMPP 90101.4. Elere Officion this issued the documents, by the two-letter cook (VMPO Standed ST). If it is unique citation comments is well as the indication of the year of the regin of the Emparter must proceed the serial number of the patient document. *Nined control in the appropriate symbols as indicated on the document of the Open the Comment of the Open Standed ST of 16 possible. *Applicant to page a class of the Standed ST of 16 possible. *Applicant to page a class make the Comment of the Open Standed ST of 16 possible. *Applicant to page a class make the Comment of the Open Standed ST of 16 possible. *Applicant to page a class make the Comment of the Open Standed ST of 16 possible. *Applicant to page a class make the Comment of the Open Standed ST of 16 possible. *Applicant to page a class make the Comment of the Open Standed ST of 16 possible. *Applicant to page a class make the Comment of the Open Standed ST of 16 possible. *Applicant to page a class make the Comment of the Open Standed ST of 16 possible. *Applicant of the Open Standed ST of 16 possible. *Applicant of the Open Standed ST of 16 possible. *Applicant of the Open Standed ST of 16 possible. *Applicant of 16 possible *Applicant of Translation is attached.

This collection of information is required by 37 CFR 1,97 and 1,98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1,14. This collection is estimated to take 2 hours to complete. TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (04-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

Examine

MAY 0 8 2003

TRADEWORT

(Use as many sheets as necessary)

Application Number	10/081,961					
Filing Date	February 22, 2002					
First Named Inventor	Gorziglia					
Art Unit	1653	TE				
Examiner Name		75				
Attorney Docket Number	4-31890					

Considered

MADE O 8 2003
CH CEN ER 1600/2900 Sheet 5 U. S. PATENT DOCUMENTS Name of Patentee or Pages, Columns, Lines, Where Publication Date Ote Document Number Applicant of Cited Document Relevant Passages or Relevant MM-DD-YYYY Figures Appear Number-Kind Code^{2 (# known)} US-HS. US. US-US-115 US-US-

		FORF	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.		Publication Date	Neme of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	١.,
II II II II		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Ľ
	1	WO 00/46355	08-10-2000			Ļ
	 	WO 00/47768	08-17-2000			_
		WO 00/56909	09-28-2000			L
	_	WO 00/67576	11-16-2000			┡
		WO 00/70071	11-23-2000			L
	1-	WO 01/02540	01-11-2001			┸

Signature "EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not "EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not received the c EXAMPLEY, mixed a reterrors conserved, whenever or not crasson as in contemnance with MeVP MAY, Unitw his envirogit classes in it not controlled about the controlled about the controlled about the controlled about the specification. A place in designation unless detailed notes designation unless detailed recipionals. See Seek (Seeks of USFTO Pattern Documents at www.usgologic.gov where 90 fb. 4. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese pattert documents, by the indication of the office of the Energe must precede the senior number of the peach comment. Yet no document by the process of the peach of the Energe must precede the senior number of the peach comment. Yet not document by the peach of the peach of

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, Use/I Up process) an apprication. Confederatory is governed by 30 US.C. 12Z and 37 CFR 1.14. The collection is estimated to last 27 hours to complete, including gathering repearing, and submitting the completed application from to the USPTO. Three MY repearing upon the middled case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Crief Information Case. The Complete Compl TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (04-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known

Substitute for form 1449/PTO

BHAT & TR

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/081,961 Filing Date February 22, 2002 First Named Inventor Gorziglia 1653 Examiner Name

(Use as many sheets as necessary) Attorney Docket Number 4-31890 of 23 Sheet 6 U. S. PATENT DOCUMENTS

Examiner initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Walfe Relevant Passages or Relevant Figures Appear
	Number-Kind Code ^{2 (F known)}			Figures Appear	
		US-			
		US-			
	-	US-			
		US-			
		US-			
	-	US-			
	-	US-			
		US-			
	1	US-			
		US-			
	t	US-			
		US-			
	1	US-			
	1	US-			
	†	US-			
		US-			
	1-	US-			
	1	US-			
	+-	US-			

Examiner Initials*	Cite No.3	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	1	Country Code ³ 'Number ⁴ 'Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	Ľ
		WO 01/04282	01-18-2001			L
		WO 01/04334	01-18-2001			L
		WO 01/23004	04-05-2001			L
	1	WO 01/36650	05-25-2001			┡
		WO 01/72341	10-04-2001			L
		WO 01/73093	10-04-2001			<u> </u>

Examine Signature

*EXAMINER: Initial if reference considered, whether or not clastion is in conformance with MPEP 600. Draw line through clastion if not in conformance and not considered, include copy of this form with next communication to applicant. *Applicant's unque citation designation number (optional). *See Kinds Codes of USPTO Patented Councients at www.useboog.or vMEP 90.1014.* *Elere follow in its issued the document by the two-letter cook VMPD Spanishes cook VMPD Spanishes (or VMPD Spanishes). *Use VMPD Spanishes of the seed and spanishes with the spanishes and s

Installation a statched.

This collection of Information is required by 37 CFR 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to tie (one by the societion) of Information is required by 38 U.SC, 172 and P.CFR 1.14. This collection of Information is considered by 38 U.SC, 172 and P.CFR 1.14. This collection of Information Considered by 38 U.SC, 172 and P.CFR 1.14. This collection is to require the information of Information Chemical Properties and P.CFR 1.14. This collection is the information Chemical Properties and Proper

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to

& TRADENS

Sheet 7

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 23

(Use as many sheets as necessary)

	Co	mplete if Known	RECE.
	Application Number	10/081,961	COUNT
	Filing Date	February 22, 2002	MAY
	First Named Inventor	Gorziglia	''' (I O ol-
	Art Unit	1653	0 2003
	Examiner Name	TEC	H CENTER 1800/290
	Attorney Docket Number	4-31890	DENTER IRDOVO
_			- 000/290

Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (FAncoun)			Figures Appear
		US-			
	-	US-			
		US-			
	-	US-			
		US-			
		US-			
		US-			
	1	US-			
		US-			
	t -	US-			
	1	US-			
	+	US-			
	+	US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Ľ
		WO 01/83796	11-08-2001			L
		WO 02/068627	09-06-2002			Г
						┝
						H
	-					

	Signature											Co	nsidered					
١	*EXAMINER:	Initial if reference	considered,	whether	or not	citation is	in cor	formance	with	MPEP	609. C	Draw lin	e throug	n citatio	n if n	ot in	confor	n

"ExcAMINER: Initial it reference considered, whether or not clasion is in commande with MeVP 609. Under line through classor in not in commande with met communication is applicant." Applicant 'surple contained estipation number (optional), "See Michie Codes of USPTO Patert Documents at <u>www.septo.og</u> or MPEP 901.04. "Enter Office that Issued the document, by the two-letter code (MPPO Standard ST.3)," for Japanese patert documents, the indication of the year of the reging of the Emperor must precise the serial number of the patert document. Not document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English language Translation is station."

Transaction or information is required by 31 CFR 137 and 1.98. The information is required to beginn or retain a benefit by the public which is to file find by the USEPTO to process) an application. Confederability is governed by 58 U.S.C. 122 and 31 CFR 1.13. This contection is offinised to take 2 house to complete, the USEPTO. This contection is offinised to take 2 house to complete, the content of the USEPTO. This well way depending upon the individual case. Any comments of the content of the USEPTO. This well way depending upon the individual case. Any comments are content of the USEPTO. This well way depending upon the individual case. Any comments are content of the USEPTO. This well way depending upon the individual case. Any comments are content of the USEPTO. This well way depending upon the individual case. Any comments are content of the USEPTO. This well way depending upon the individual case. Any comments are content of the USEPTO. This well way depending upon the individual case. Any comments are content of the USEPTO. This well way depending upon the individual case. Any comments are content of the USEPTO. This well was depended upon the individual case. Any comments are content of the USEPTO. This well was depended upon the individual case. Any comments are content of the USEPTO. This well was depended upon the individual case. Any comments are content of the USEPTO. The well-known that the content of the USEPTO. The well-known the individual case. Any comments are content of the USEPTO. The well-known that the use of the USEPTO. The use of the use

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031

4-31890A

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE or the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known titute for form 1449/PTO Application Number 10/081.961 INFORMATION DISCLOSURE Filing Date February 22, 2002 STATEMENT BY APPLICANT First Named Inventor Gorziolia Art Unit 1653 (Use as many sheets as necessary) Examiner Name

Attorney Docket Number

23

of

Sheet 8

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Examiner Cite the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue T² No. Initials* number(s), publisher, city and/or country where published. ADAMS, et al., "Transcriptional Control by E2F," Seminars in Cancer Biology, 6:99-108 (1995) ALEMANY, et al., "Replicative Adenoviruses for Cancer Therapy," Nature Biotechnology, 18:723-727 (July 2000) ANGELICHIO, et al., "Comparison of Several Promoters and Polyadenylation Signals for Use in Heterologous Gene Expression in Cultured Drosophila Cells," Nucleic Acids Research, 19(18):5037-5043 (1991) ARMITAGE, J., "Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," Blood, 92(12):4491-4508 (December 15, 1998) BABISS, et al., "Cellular Promoters Incorporated into the Adenovirus Genome: Effects of Viral Regulatory Elements on Transcription Rates and Cell Specificity of Albumin and Beta-Globin Promoters," Molecular and Cellular Biology, 6(11):3798-3806 (November 1986) BERGSLAND, et al., "Shedding Old Paradigms: Developing Viruses to Treat Cancer," Journal of Clinical Oncology, 20(9):2220-2222 (May 1, 2002) BERT, et al., "Generation of an Improved Luciferase Reporter Gene Plasmid that Employs a Novel Mechanism for High-Copy Replication," Plasmid, 44:173-182 (September 2000) BLACK, et al., "Regulation of E2F: A Family of Transcription Factors Involved in Proliferation Control," Gene, 237:281-302 (1999) BRISTOL, et al., "GM-CSF Containing Oncolytic Adenoviruses for the Treatment of Cancer." Abstract No. P2, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002 BRISTOL, et al., "GM-CSF Mediated Stimulation of Innate Anti-tumor Responses," poster presented at the Keystone Symposia, Basic Aspects of Tumor Immunology, February 17-23, 2003

Examiner Signature	Date Considered
Signature	Do a time there are not been if not in conformance and not

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

consistent. Include copy of this offer with new communication to experient.

Application's unique claims designation under (epidons) 2 opportunit to place a check mark here if English language Translation's sittlends which is the (set of the place) and the place and t gathering, preparing, and submitting the completed application form to the USPTC. Time will vary depending upon the individual case. Any comments on the amount of irre you require to complete his form and/or suggestions for reducing his burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (04-03) Approved for use through 04/30/2003. DMB 0651-0031 ant and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Und the Paperwork Reduction Act of 1995, no past	sons are required to respond to a concess.	required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known				
BA Mute for form 1449/PTO	Application Number	10/081,961				
INFORMATION DISCLOSU	RE Filing Date	February 22, 2002	REOF			
STATEMENT BY APPLICA		Gorziglia	-CE/			
	Art Unit	1653	MAY			
(Use as many sheets as necessary)	Examiner Name	7	FC11 8 200			
Sheet 9 of 23	Attorney Docket Number	4-31890A	-UT CENTER			
			-117600/			

		THE PARTY OF THE P	
Examiner	Cite No.1	NON PATENT LITERATURE DOCUMENTS NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the tem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T ²
Initials*	No.	number(s), publisher, city and/or country where published.	
		BRISTOL, et al., "GM-CSF Containing Oncolytic Adenoviruses for the Treatment of Cancer," poster presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2009.	
		BRISTOL, et al., "In Vivo Anti-Tumor Activity of Oncolytic Adenoviruses that Express GM-CSF in Xenograft Tumor Models," American Society for Gene Therapy, 5th Annual Meeting, June 5-9, 2002; poster presented June 6, 2002	
		BRISTOL, et al., "In Vivo Anti-Tumor Activity of Oncolytic Adenoviruses that Express GM-CSF in Xenograft Tumor Models," Molecular Therapy, 5(5):abstract No. 311 (May 2002)	
		BRUDER, et al., "Nuclear Factor Ef-1A Binds to the Adenovirus E1A Core Enhacer Element and to Other Transcriptional Control Regions," Molecular and Cellular Biology, 9(11):5143-5153 (November 1989)	
		BRYAN, et al., "Evidence for an Alternative Mechanism for Maintaining Telomere Length in Human Tumors and Tumor-derived Cell Lines," Nature Medicine, 3(11):1271-1274 (November 1997)	
		CHANG, et al., "Immunogenetic Therapy of Human Melanoma Utilizing Autologous Tumor Cells Transduced to Secrete Granulocyte-Macrophage Colony-Stimulating Factor," Human Gene Therapy, 11:393-850 (April 10, 2000)	
		CHAO, et al., "Assembly of the Cleavage and Polyadenylation Apparatus Requires About 10 Seconds in Vivo and is Faster for Strong Than for Weak Poly(A) Sites," Molecular and Cellular Biology, 19(8):5588-5600 (August 1999)	
		CHEN, et al., "Antiangiogenic Gene Therapy for Cancer via Systemic Administration of Adenoviral Vectors Expressing Secretable Endostatin," Human Gene Therapy, 11:1983-1996 (September 20, 2000)	
		CHEN, et al., "Cleavage Site Determinants in the Mammalian Polyadenylation Signal," Nucleic Acids Research, 23(14):2614-2620 (1995)	L
		CHIA, et al., "A Novel Conditionally Oncolytic Adenovirus for the Treatment of Nasopharyngeal Carrinoma (NPC)," Proceedings of the American Association for Cancer Research, 43:1098-1099, abstract No. 5441 (March 2002)	

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not distrion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of the form with near communication to agelitation. Application's using calculation designation under portional, a Special set to place a check mark here if English ungage, Transition's patiented. This collection of information is required by 37 CFR 18. The reformation is required by 30 CFR 18. The reformation is extracted to take 120 minutes to complete, including to proceed application from the total PST 19. The reformation is extracted to take 120 minutes to complete, including an amount of time you require to complete applications from the total PST 18. The reformation is the second of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the CHR Internation Charles 18. PST 18. The PST 18 Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. CMB 0651-0031

U.S. Patent and Treadermark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid CMB control number.

3 WAY 0			uction Ac	t of 1995, no persons ar	a required to respond to a collection	and Trademark Office; U.S. DEF of information unless it contains Complete if Known	a valid OMB control number.
W. IH	Dewastitus	e for form 1449/PTO			Application Number	10/081,961	Pr-
					Filing Date	February 22, 2002	CEIVE
	STA	STATEMENT BY APPLICANT			First Named Inventor	Gorziglia	MAY
					Art Unit	1653	7003
	(Use as many sheets as necessary)				Examiner Name		TECH CENTED
	Sheet	10	of	23	Attorney Docket Number	4-31890A	TEH 1600/2900
	-		1 0				~~000

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHIOCCA, E., "Oncolytic Viruses," Nature, 2-938-950 (December 2002)	
		CHRIST, et al., "Modulation of the Inflammatory Properties and Hepatotoxicity of Recombinant Adenovirus Vectors by the Viral E4 Gene Products." Human Gene Therapy, 11:415-427 (February 10, 2000)	
		COLGAN, et al., "Mechanism and Regulation of mRNA Polyadenylation," Genes and Development, 11:2755-2766 (1997)	
		CURIEL, et al., "Strategies to Improve the Therapeutic Utility of Conditionally Replicative Adenoviruses (CRAds) for Cancer Therapy," Proceedings of the American Association for Cancer Research, 43.662, abstract No. 3287 (Macrit 2002)	
		DEMERS, et al., "Antitumor Efficacy and Replication of an Oncolytic Adenovirus, 01/PEME, in Tumor Tissue Following Intravenous Administration," Proceedings of the American Association for Cancer Research, 43.663, obstract No. 3291 (March 2002)	
		DENOME, et al., "Patterns of Polyadenylation Site Selection in Gene Constructs Containing Multiple Polyadenylation Signals," Molecular and Cellular Biology, 8(11),4829-4839 (November 1988)	
		DeWeese, et al., "A Phase I Trial of CV706, a Replication-Competent, PSA Selective Oncolytic Adenovirus, for the Treatment of Locally Recurrent Prostate Cancer Following Radiation Therapy," Concert Pageage 16:1246-2472 (October 15, 2001)	
		DORONIN, et al., "Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy," Journal of Virology, 75(7):3314-3324 (April 2001)	
		DORONIN, et al., "Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein," Journal of Virology, 74(13):6147-6155 (July 2000)	
		DRANOFF, et al., "Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulatus Potent, Specific, and Long-Lasting Anti-Tumor Immunity," Proc. Natl. Acad. Sci. USA, 90:3339-3451 (April 1993)	

		Date	
Examiner		Considered	
Signature	TV A1000 00		itation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered, include copy of this form with next communication to applicant.

considered. Include copy of the form with rest communication to appreciate.

1 Applicant's unique citizend exignation number (optional, 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citizend exignation number (optional, 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citizend in equired by 37 CFR 198. The information is required to obtain or retain a benefit by the public which is to like (and by the USPTO. The control is estimated to take 120 minutes to complete a control in the completed application. Confiderable by geometry 59 CSR 1, 122 and 37 CFR 114. This collection is estimated to take 120 minutes to complete application. Confiderable by geometry 59 CSR 1, 122 and 37 CFR 114. This collection is estimated by the interval of the confiderable application. Confiderable is geometry 50 CSR 1, 122 and 127 CSR 1, 123 CSR 1

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0551-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE

`		Complete if Known	U.S. Patent a	TOT 1990, NO PERSONS OF	CION AC	er the Paperwork Reou	ADEMA
		10/081,961	Application Number			e for form 1449/PTO	Substitut
_	TEC	February 22, 2002	Filing Date	CLOSURE	DIS	DRMATION	INFO
	M	Gorziglia	First Named Inventor	PPLICANT			
4	- "AY 0	1653	Art Unit				
_	IECH CENT		Examiner Name	ecessary)	ets as n	(Use as many she	
ز	LIVIER	4-31890A	Attorney Docket Number	23	of	11	Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DYSON, N., "The Regulation of E2F by pRB-family Proteins," Genes and Development, 12:2245-2262 (August 1998)	
		EMERY, et al., "A Chromatin Insulator Protects Retrovirus Vectors from Chromosomal Position Effects," Proc. Natl. Acad. Sci. USA, 97(16):9150-9155 (August 1, 2000)	
		ENNIST, D., "Oncolytic Adenoviruses Containing GM-CSF for the Treatment of Cancer," oral presentation at the 4th International Conference, The Adjuvant Therapy of Malignant Melanoma, March 15-16, 2002	
		ENNIST, D., "Oncolytic Adenoviruses Containing GM-CSF for the Treatment of Cancer," abstract presented at the 4th International Conference, The Adjuvant Therapy of Malignant Melanoma, March 15-16, 2002	
		ENNIST, et al., "Oncolytic Adenoviruses Containing GM-CSF for the Treatment of Cancer." Proceedings of the American Association for Cancer Research, 43:1098, abstract No. 5437 (March 2002)	
		ENNIST, et al., "Oncolytic Adenoviruses Containing GM-CSF for the Treatment of Cancer," oral presentation at the 93rd Annual Meeting of the American Association for Cancer Research, April 6-10, 2002, San Francisco, California	
		FALLAUX, et al., "New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses," Human Gene Therapy, 9:1909-1917 (September 1, 1998)	
		FANG, et al., "Diminishing Adenovirus Gene Expression and Viral Replication by Promoter Replacement," Journal of Virology, 71(6):4798-4803 (June 1997)	
		FRIDOVICH-KEIL, et al., "Improved Expression Vectors for Eukaryotic Promoters-Enhancer Studies," BioTechniques, 11(5):572-579 (1991)	
		GANLY, et al., "A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer," Clinical Cancer Research, 6:798-808 (March 2000)	

		$\overline{}$
Examiner	Date	- 1
	Considered	
Signature	Collsidered	_

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

A pipilicant's unique claim designation number (options), 2 applicant is to place a check mate have 1 English transpairs Translation is statistical.

This collection of information is required by 37 CFR 18. The left cradiation is considered by the public which is to file (and by the USPTO This collection of information is required by 37 CFR 18. The left cradiation of the considered by the public which is to file (and by the USPTO process) an applicant to the 120 minutes to complete, including to process the considered subcritisting the comprised applications from the trust USPTO. Three will vary depending upon the included case. Any comments on the amount of time by unique to complete this form and/or suggestions for reducing this surface, should be sent to the Observation of Comments and Comments of the surface of the Comments of the Co Commissioner for Patents, Washington, DC 20231.

Approved for use through CALCONNESS (MASS)

U.S. Peter and Theirmen Control of U.S. Calconness (M. CALCONNESS (Complete if Known

Šh.	NEW TO	er their aperiron.			e required to respond to a collection	Complete if Known	
TRAI	Ander the Paperwork Reduction Act of 1995, no. p				Application Number	10/081,961	REC
	INFO	ORMATIC	N DIS	CLOSURE	Filing Date	February 22, 2002	
	STATEMENT BY APPLICANT		First Named Inventor	Gorziglia	MAY		
					Art Unit	1653	TECU
	(Use as many sheets as necessary)				Examiner Name		CENTED
	Sheet	12	of	23	Attorney Docket Number	4-31890A	

		NON PATENT LITERATURE DOCUMENTS	
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Git., et al., "Position-Dependent Sequence Elements Downstream of AAUAAA Are Required for Efficient RabbitGlobin mRNA 3' End Formation," Cell, 49:399-406 (May 8, 1987)	
		GOPE, et al., "Abundance and State of Phosphorylation of the Retinoblastoma Susceptibility Gene Product in Human Colon Cancer," Molecular and Cellular Biochemistry, 110:123-133 (1992)	
		GU, et al., "Tumor-Specific Transgene Expression from the Human Telomerase Reverse Transcriptase Promoter Enables Targeting of the Therapeutic Effects of the Bax Gene to Cancers," Cancer Research, 60:5359-5364 (October 1, 2000)	
		HABIB, et al., "E18-Deleted Adenovirus (d11520) Gene Therapy for Patients with Primary and Secondary Liver Tumors," Human Gene Therapy, 12:219-226 (February 10, 2001)	
		HALLENBECK, et al., "A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma," Human Gene Therapy, 10:1721-1733 (July 1, 1999)	
		HALLENBECK, et al., "Oncolytic Adenoviruses Dependent Upon Two Prevalent Alterations in Human Cancer; Disregulation of the RB-Pathway and Telomerase," American Society of Gene Therapy 5th Annual Meeting, June 5-9, 2002, poster presented on June 5-, 2002	
		HALLENBECK, et al., "Oncolytic Adenoviruses Dependent Upon Two Prevalent Alterations in Human Cancer; Disregulation of the RB-Pathway and Telomerase," Molecular Therapy, 5(5) Abstract 165 (May 2002)	
		HALLINBECK, P., "Oncolytic Adenoviruses Dependent Upon Two Prevalent Alterations in Human Cancer; Disregulation of the Rb-Pathway and Telomerase," or all presentation presented at the 3rd International Symposium on Genetic Anticancer Agents, Amsterdam, The Netherlands, March 1-2, 2002	
		HANS, et al., "Functionally Significant Secondary Structure of the Simian Virus 40 Late Polyadenylation Signal," Molecular and Cellular Biology, 20(8):2926-2932 (April 2000)	
		HATFIELD, et al., "Redundant Elements in the Adenovirus Type 5 Inverted Terminal Repeat Promote Bidirectional Transcription In Vitro and Are Important for Virus Growth In Vivo," Virology, 184:265-276 (1991)	

Examiner	Date
Signature	Considered
Olgitature	in AUDED 600. Describes through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not distallon is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, houside copy of this form with next communication to applicant.

Applicant's using circlaim objective counter (policinal), a popilicant is to place a check make use Egiptic Interpope Translation is attached.

1 Applicant's using circlaim objective counter (policinal), a popilicant is to place a check make use of use in permitting the centre of the Counter of the coun Commissioner for Patents, Washington, DC 20231.

Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				t of 1995, no persons an	e required to respond to a collection	Complete if Known	S & Valid Comb Control Hornes
SUbstitute for form 1449/PTO					Application Number	10/081,961	
	INFO	RMATIO	N DIS	CLOSURE	Filing Date	February 22, 2002	- DA
				PPLICANT	First Named Inventor	Gorziglia	
					Art Unit	1653	Mar
		(Use as many s	heets as n	necessary)	Examiner Name		TEA 082
ļ	Sheet	13	of	23	Attorney Docket Number	4-31890A	CH CENTER

			10(1/1/
		NON PATENT LITERATURE DOCUMENTS	1000/2
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HATFIELD, et al., "The NFIII/OCT-1 Binding Site Stimulates Adenovirus DNA Replication in Vivo and is Functionally Redundant with Adjacent Sequences," Journal of Virology, 67(7):3931-3939 (July 1993)	
		HAY, C., "Oncolytic Adenovirus Dependent Upon Two Prevalent Alterations in Human Cancer," The 10th Annual Meeting of the European Society of Gene Therapy, Antibes, France, October 13-16, 2002, oral presentation presented on October 16, 2002	L
		HEARING, et al., "The Adenovirus Type 5 E1A Transcriptional Control Region Contains a Duplicated Enhancer Element," Cell, 33:895-703 (1983)	
		HEISE, et al., "Efficacy of a Replication-Competent Adenovirus (ONYX-015) Following Intratumoral Injection: Intratumoral Spread and Distribution Effects," Cancer Gene Therapy, 6(6):499-504 (1999)	
		HEISE, et al., "Replication-Selective Adenoviruses as Oncolytic Agents," The Journal of Clinical Investigation, 105(7):847-851 (April 2000)	
		HERMISTON, T., "Gene Delivery From Replication-Selective Viruses: Arming Guided Missiles in the War Against Cancer," The Journal of Clinical Investigation, 105(9):1169-1172 (May 2000)	
		HIYAMA, et al., "Teiomerase Activity in Small-Cell and Non-Small-Cell Lung Cancers," Journal of the National Cancer Institute, 87(12):895-902 (June 21, 1995)	
		HORIKAWA, et al., "Cloning and Characterization of the Promoter Region of Human Telomerase Reverse Transcriptase Gene," Cancer Research, 59:826-830 (February 15, 1999)	
		HURFORD, et al., "pRB and p107/p130 are Required for the Regulated Expression of Different Sets of E2F Responsive Genes," Genes & Development, 11:1447-1463 (1997)	
		HWANG, et al., "Polyadenylation of Vesicular Stomatitis Virus mRNA Dictates Efficient Transcription Termination at the Intercistronic Gene Junctions," Journal of Virology, 72(2):1805-1813 (March 1998)	

Formations.	Date
Examiner	Considered
Signature	20 To a second with MPEP 609. Draw fine through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique clastic designation number (opcoing). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique clastic designation number (opcoing). 2 Applicant is to place a check mark here if English language Translation is attached.

1 This colection of information is required by a great part of the control of the con Commissioner for Patents, Washington, DC 20231.

Approved for use through 04/30/2003. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PARETIME for form 1449/PTO		Complete if Known		4
AADentue for form 1449/PTO	Application Number	10/081,961	ME	h_
INFORMATION DISCLOSURE	Filing Date	February 22, 2002		KIVE
STATEMENT BY APPLICANT	First Named Inventor	Gorziglia	To MAY O	1 52
	Art Unit	1653	CH Con	2003
(Use as many sheets as necessary)	Examiner Name		OLIVIER,	
Sheet 14 of 23	Attorney Docket Number	4-31890A		700/29 ₀₀
				٦ '''

		NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Examiner Initials*	Cite No.1	Include name of the author (in CAFTHA serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		International Search Report for PCT/US02/05280, February 14, 2003	
		JAFFEE, et al., "Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Cancer. A Phase I Tind of Safety and Immune Activation," Journal of Clinical Oncology, 19(1):145-156 (January 1, 2001)	
		JAKUBOZAK, et al., "Construction and Characterization of Oncolytic Adenoviruses," Molecular Therapy, 3(5):Abstract 442 (May 2001)	
		JAKUBCZAK, et al., "Construction and Characterization of Oncolytic Adenoviruses," The Fourth Annual Meeting of the American Society of Gene Therapy, May 30-June 3, 2001; poster presented on June 1, 2001	
		JAKUBCZAK, et al., "Evaluation of in Vivo Selectivity of Oncolvipt, Adenoviruses Following Intravenous Administration in SCID Mice Using Toxicological and Molecular Parameters," American Society of Gene Therapy, 5th Annual Meeting, June 5 9, 2002; poster presented June 7, 2002	L
		JAKUBCZAK, et al., "Evaluation of in Vivo Selectivity of Oncolytic Adenoviruses Following Intravenous Administration in SCID Mice Using Toxicological and Molecular Parameters," Molecular Therapy, 5(5): abstract No. 851 (March 2002)	
		JAXUBCZAK, J., "An Oncolytic Adenovirus Dependent Upon Two Prevalent Alterations in Human Cancer; Disregulation of the Rt-Pathway and Telomerase," or all pseentation presented at the US-Japan Cooperative Cancer Research Program, Telomeras and Telomerase in Cancer Research, Maul, HI, August 3-5, 2002	
		JOHNSON, et al., "Autoregulatory Control of E2F1 Expression in Response to Positive and Negative Regulators of Cell Cycle Progression," Genes and Development, 8:1514-1525 (1994)	
		JOHNSON, et al., "Cytosine Deaminase-armed Selectively Replicating Adenovirus for the Treatment of Cancer," Proceedings of the American Association for Cancer Research, 43:656. abstract No. 3257 (March 2002)	L
		JOHNSON, et al., "Selectively Replicating Adenoviruses Targeting Deregulated E2F Activity are Potent, Systemic Antitumor Agents," Cancer Cell, 1:325-337 (May 2002)	

		_
Examiner Signature	Date Considered	╛

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to spotland.

1 Applican's funding chains of selegration control (copient). 2 Applican's to place a check mark here if English language Translation is attached.

1 Applican's funding chains of the communication of the co Commissioner for Patents, Washington, DC 20231.

PTOSB088 (04-03)
Approved for use through 04/03/03 OMB 054-039
U.S. Panent and Tandemak Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information uses it contains a variety OMB control number.

Commission of Various stitute for form 1449/PTO Application Number 10/081,961

Sheet 15

TECH CENTER 1600/2900 February 22, 2002 INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor Gorziglia 1653 (Use as many sheets as necessary) Examiner Name Attorney Docket Number 4-31890A 23 of

		NON PATENT LITERATURE DOCUMENTS	_
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KAELIN, et al., "Expression Cloning of a cDNA Encoding a Retinoblastoma-Binding Protein with E2F-like Properties," Cell, 70:351-364 (July 24, 1992)	
		KESSLER, et al., "Requirement of A-A-U-A-A and Adjacent Downstream Sequences for SV40 Early Polyadenylation," Nucleic Acids Research, 14(12):4939-4953 (1986)	
		KILIAN, et al., "Isolation of a Candidate Human Telomerase Catalytic Subunit Gene, Which Reveals Complex Splicing Patterns in Different Cell Types," Human Molecular Genetics, 6(12):2011-2019 (1997)	
		KIM, et al., "Spedific Association of Human Telomerase Activity with Immortal Cells and Cancer," Science, 266:2011-2015 (December 23, 1994)	
		KIRN, D., "Clinical Research Results with d1520 (Onyx-015), a Replication-selective Adenovirus for the Treatment of Cancer: What Have We Learned?" Gene Therapy, 8.89-98 (January 2001)	
	T	KIRN, D., "Replication-selective Microbiological Agents: Fighting Cancer With Targeted Germ Warfare," The Journal of Clinical Investigation, 105(7):837-839 (April 2000)	L
		KIRN, D., "Replication-selective Oncolytic Adenoviruses: Virotherapy Aimed at Genetic Targets in Cancer," Oncogene, 19:6660-6669 (December 27, 2000)	
		KIRN, D., "Virotherapy for Cancer: Current Status, Hurdles, and Future Directions," Cancer Gene Therapy, 9:959-960 (December 2002)	
		KIRN, et al., "ONYX-015: Clinical Data are Encouraging," Nature Medicine, 4(12):1341-1342 (December 1998)	
		KIRSCHWEGER, G., "Genetic Therapies, Inc.: Tight-Lipped for Now," Molecular Therapy, 7(3):293 (March 2003)	

Examiner	Date Considered	
Signature		The second secon

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609.

considered, include copy of this form with next communication to applicant.

Applicant is using usided neighbors of manufacture (applicant) as populated is to place a check may not place (applicant place).

This collection of information is required by 37 CFR 18. The Information is required to a period by the public which is to file (and by the USPTO This collection of information is required by 37 CFR 18. The Information is required by 38 CFR 18. The Information is estimated to take 120 minutes to complete, including to processal in applicant consisting when the Information is estimated to take 120 minutes to complete applications from the USPTO. This will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or supplications for reducing his burden, should be sent to the Order 18. The Information CFR 18. The Inform Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE s it contains a valid OMB control number.

	Complete if Known			
Pade finute for form 1449/PTO	Application Number	10/081,961		
INFORMATION DISCLOSURE	Filing Date	February 22, 2002 RECEN		
STATEMENT BY APPLICANT	First Named Inventor	Gorziglia		
	Art Unit	1653 MAY 0 8 30		
(Use as many sheets as necessary)	Examiner Name	TECHOR		
Sheet 16 of 23	Attorney Docket Number	4-31890A 077 CENTER 1600		

		NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate), title of the article (when appropriate).	
Examiner Initials*	Cite No.1	the item (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), relative tem (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), date, page(T ²
		KIYONO, et al., "Both Rb/p16lNK4a Inactivation and Telomerase Activity are Required to Immortalize Human Epithelial Cells." Nature, 396:84-88 (November 5, 1998)	
		KOVESDI, et al., "Identification of a Cellular Transcription Factor Involved in E1A Trans-Activation," Cell, 45:219-228 (April 25, 1986)	
		KURIHARA, et al., "Selectivity of a Replication-Competent Adenovirus for Human Breast Carcinoma Cells Expressing the MUC1 Antigen," The Journal of Clinical Investigation, 105(6):78-71 (September 2000)	
		KWONG, et al., "Combination Therapy with Suicide and Cytokine Genes for Hepatic Metastases of Lung Cancer," Chest, 112(5):1332-1337 (November 1997)	
		LA THANGUE, N., "DRTF1/E2F: An Expanding Family of Heterodimeric Transcription Factors Implicated in Cell-Cycle Control," Trends in Biochemical Science, 19:108-114 (March 1994)	
		Li, et al., "A Hepatocellular Carcinoma-specific Adenovirus Variant, CV890, Eliminates Distant Human Liver Tumors in Combination with Doxorubicin," Cancer Research, 61:6428-6438 (September 1, 2001)	L
		Li, et al., "Replication Competent Oncolytic Adenovirus for Colon Cancer Therapy," Proceedings of the American Association for Cancer Research, 43:858, abstract No. 4251 (March 2002)	L
		LIMBACH, et al., "Development of Adenovrus Serotype 35 as a Gene Transfer Vector," poster presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002.	
		LIU, et al., "Optimised Oncolytic Herpes Simplex Virus for Cancer Treatment," Abstract No. Or33, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, Econo. October 13:18, 2002.	L
		I'ul, et al., "Optimized Oncolytic Herpes Simplex Virus for Cancer Treatment." poster presented at the 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002	

	Date
Examiner	Considered
Signature	performance and not

^{*}EXAMMER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of his form with next communication to splication.

1 Applicant's unique clashon designation number (policy application to place a check mark here if English language Translation is attached.

1 Applicant's unique clashon designation number (policy application to place a check mark here if English language Translation is attached.) The collection of unique to the place of the policy and the place of the pl

Processing (04-03)
Approved for use through 04/03/03/03. ONE 085-03/03
U.S. Palent and Tradformic Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information intensis i contains a valid Oldific control number.

Complete if Known tute for form 1449/PTO **Application Number** 10/081,961 February 22, 2002 INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor Gorziglia Art Unit 1653 (Use as many sheets as necessary) Examiner Name Attorney Docket Number 4-31890A 23 Sheet 17

		NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
xaminer nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volune-issue number(s), publisher, city and/or country where published.	T ²
		LORENCE, et al., "Systemic Therapy of Human Turnor Xenografis Using PV701, an Oncolytic Strain of Newcastle Disease Virus, in Combination with a Cytotack Drug Demonstrates at Least Additive Anticumor Responses," Proceedings of the American Association for Cancer Research, 43:1096, abstract No. 5428 (March 2002)	
		LYONS, R., "Multiple Approaches to Treating Systemic Disease with Oncolytic Adenoviruses," ASM Gene Therapy Conference, February 28, 2003, Banff, Alberta CA; oral presentation presented February 28, 2003	
		MABJESH, et al., "Gene Therapy of Prostate Cancer: Current and Future Directions," Endocrine-Related Cancer, 9:115-139 (June 2002)	
		McDEVITT, et al., "Sequences Capable of Restoring poly(A) Site Function Define Two Distinct Downstream Elements," The EMBO Journal, 5(11):2907-2913 (1986)	
		MEDINA, et al., "Adenovirus-Mediated Cytotoxicity of Chronic Lymphocytic Leukemia Cells," Blood, 94(10):3499-3508 (November 15, 1999)	
		MORRIS, et al., "Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk," Molecular Therapy, 1(1):58-62 (January 2000)	
		NEMUNAITIS, et al., "Selective Replication and Oncolysis in p53 Mutant Tumors with ONYX-015, an E18-55kD Gene-Deleted Adenovirus, in Patients with Advanced Head and Neck Cancer: A Phase II Trial, "Cancer Research, 06:0359-6366 (November 15, 2000)	L
		NEUMAN, et al., "Structure and Partial Genomic Sequence of the Human E2F1 Gene," Gene, 173:163-169 (1996)	
		NEUMAN, et al., "Transcription of the E2F-1 Gene is Rendered Cell Cycle Dependent by E2F DNA-Binding Sites Within its Promoter," Molecular and Cellular Biology, 14(10) 6607-6615 (October 1994)	
		OH, et al., "In Vivo and In Vitro Analyses of Myc for Differential Promoter Activities of the Human Telomerase (hTERT) Gene in Normal and Tumor Cells," Biochemical and Biophysical Research Communications, 283:361-366 (1999)	

	Communication		
Examiner		Date Considered	
Signature	and the law is in conformance with MPEP 60		tation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance a considered. Include copy of this form with next communication to applicant.

considered, Include copy of this form with near communication to agricultural.

Applicant's unsuper calcitation designation number (optional). 2 Speptians it is bytica a check mark here if pright ingrapes Transition is subched.

Tapicitatis unsuper calcitation designation number (optional). 2 Speptians is to bytica a check mark here if pright ingrapes which is to file (not by the USPTO This collection of information is required by 37 CFR 18. The reformation is required 14. The collection is estimated to take 120 initiates to complete, including processal an application. Confidentiation of completed application from the But USPTO. Time will vary depending upon the industrial case. Any commission of the processal in application of the processal application of th Commissioner for Patents, Washington, DC 20231.

Approved for use strong house (MA).

U.S. Parint and Transaction of the U.S. Parint and Transaction (MA) control number (MA).

U.S. Parint and Transaction (MA) control number (MA) and Transaction (MA) control number (MA).

S. THAPE Complete if Known MAY 0 8 2003
TECH CENTER 1600/2900 ubstitute for form 1449/PTO **Application Number** 10/081,961 INFORMATION DISCLOSURE Filing Date February 22, 2002 STATEMENT BY APPLICANT First Named Inventor Gorziglia Art Unit 1653 (Use as many sheets as necessary) Examiner Name Attorney Docket Number 4-31890A 23 Sheet 18 of

	T	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
xaminer nitials*	Cite No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PAIELLI, et al., "Evaluation of the Biodistribution, Persistence, Toxicity, and Potential of Germ-Line Transmission of a Replication-Competent Human Adenovirus Following Intraprostatic Administration in the Mouse, Mole	
		PARDOLL, D., "Paracrine Cytokine Adjuvants in Cancer Immunotherapy," Annu. Rev. Immunol., 13:399-415 (1995)	
		PARR, et al., "Tumor-selective Transgene Expression In Vivo Mediated by an E2F-responsive Adenoviral Vector," Nature Medicine, 3(10):1145-1149 (October 1997)	
		PECORA, et al., "Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers," Journal of Clinical Oncology, 20(9):2251-2266 [May 1, 2002]	
		PETER, et al., "A Novel Attenuated Replication-Competent Adenovirus for Melanoma Therapy," Abstract No. P78, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibos, France, October 13-16, 2002	
		POOLE, et al., "Activity, Function, and Gene Regulation of the Catalytic Subunit of Telomerase (hTERT)," Gene, 269:1-12 (May 2001)	
		POROSNICU, et al., "Increased Efficiency of the Selectively Oncodytic Vesicular Stomatitis Virus by Genetic Manipulation with Expression of Suicide Genes," Proceedings of the American Association for Cancer Research, 43:1086-1097, abstract No. 431 (March 2002).	L
		POWELL, et al., "A Conditionally Replicative Adenovirus Driven by the Human Telomerase Promoter Provides Broad-Spectrum Anti-Tumor Activity," Molecular Therapy, 5(5): abstract No. 51 (May 2022)	
		PRELL, et al., "Tumor Necrosis Factor (-armed Defective p53-pathway Selective Replicating Adenovirus for Cancer Treatment," Proceedings of the American Association for Cancer Research, 43:1110, abstract No. 5500 (March 2002)	L
		RAMACHANDRA, et al., "Re-engineering Adenovirus Regulatory Pathways to Enhance Oncolytic Specificity and Efficacy," Nature Biotechnology, 19:1035-1041 (November 2001)	

Examiner Signature	Date Considered
Signature	to the conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique chaton designation number (options). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 37 CFR 1.98. INSTACHED OF INTERNATION AND INTERNATION AND INTERNATION IS REQUIRED TO DOBBIT OF REAL OF THE PROPERTY OF THE Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Bider the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of alternation unless it contains a valid OMB control number.

Substitut	e for form 1449/PTO			Application Number	10/081,961	
INF	ORMATION	DIS	CLOSURE	Filing Date	February 22, 2002	RES
			PPLICANT	First Named Inventor	Gorziglia	. 120
•				Art Unit	1653	MAY
	(Use as many she	ets as n	ecessary)	Examiner Name		Tro
Sheet	19	of	23	Attorney Docket Number	4-31890A	IECH CENTER

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Examiner Cite T^2 the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No. Initials* number(s), publisher, city and/or country where published RASCHKE, et al., "A Replication Competent Dual-ad Vector for Treatment of Prostate Cancer." Abstract No. Or41, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002 RASSA, et al., *Molecular Basis for Naturally Occurring Elevated Readthrough Transcription Across the M-F Junction of the Paramyxovirus SV5," Virology, 247:274-286 (1998) REDDY, et al., "Development of Adenovirus Serotype 35 as a Gene Transfer Vector," American Society of Gene Therapy 5th Annual Meeting, June 5-9, 2002, poster presented June 6, 2002 REDDY, et al., "Development of Adenovirus Serotype 35 as a Gene Transfer Vector," American Society of Gene Therapy 5th Annual Meeting, June 5-9, 2002, Molecular Therapy, 5(5):S67-S68, abstract No. 200 RESZKA, et al., "New Targeting System for High-efficient Delivery of Anti-neoplastic Drugs or Genes into the Angiogenetic Areas of Liver Tumors," Proceedings of the American Association for Cancer Research, 43:663, abstract No. 3289 (March 2002) RIES, et al., "ONYX-015: Mechanisms of Action and Clinical Potential of a Replication-Selective Adenovirus," British Journal of Cancer, 86:5-11 (January 7, 2002) RODRIGUEZ, et al., "Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells," Cancer Research, 57:2559-2563 (July 1, 1997) RUSSELL, W., "Update on Adenovirus and Its Vectors," Journal of General Virology, 81:2573-2604 (November 2000) RYAN, et al., "An Oncolytic Adenovirus Dependent on Two Prevalent Alterations in Human Cancer: Efficacy, Tolerability, and Tumor-Selectivity Following Systemic Administration," Eleventh International Conference on Gene Therapy of Cancer, San Diego, CA, December 12-14, 2002, 10(Suppl. 1):abstract No. 036 RYAN, et al., "Anti-Tumor Efficacy and Preclinical Proof-of-Concept Following Systemic Administration of an Oncolytic Adenovirus Dependent Upon Two Prevalent Alterations in Human Cancer," Abstract No. Or34, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002

Examiner		Date Considered	ł
Signature	1	and a second sec	nce and not

EXAMINER: Initial if reference considered, whether or not obtains is in conformance with MPEP 609. Oraw line through chatton if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique clation designation number (optionsi). 2 Applicant is to place a check mark here if English language Translation a sitabol.

This collection of information is required by 37 CR 1 198. The information is required to obtain or retain a benefit by the public which is to life (end by the USPTO This collection of information is required by 37 CR 1 198. The information is required to obtain or retain a benefit by the public which is to life (end by the USPTO The process) an application. Confidentiality is governed by 38 USE. 1 22 and 37 CR 11.4. This collection is estimated to be less than the complete adaptication form to the USPTO. Time what vary depending upon a distribution of the complete adaptication form to the USPTO. The way what yet depending upon the chief information Officer. U.S. Palent and amount of time you require to complete his flow and/or suppressions for reducing this burder, should be sent the Chef Information Officer. U.S. Palent and Trademark Office. U.S. Capariment of Commerce. Washington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Palents, Washington, OC 20231.

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

BIHATEL	UNA the Penerunik Red	luction Ac	t of 1995, no persons are	a movined to respond to a collection	Approved for use through 0 and Trademark Office; U.S. DEP of information unless it contains a	
ALT.	Substitute for form 1449/PTO			Application Number	Complete if Known 10/081,961	Dr
	INFORMATION	I DIS	CLOSURE	Filing Date	February 22, 2002	MECEIVE
	STATEMENT I			First Named Inventor	Gorziglia	MAY
				Art Unit	1653	8 200
	(Use as many sh	eets as n	ecessary)	Examiner Name	11.	CH CENTED
	Sheet 20	of	23	Attorney Docket Number	4-31890A	1600/2900

		NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), little of	
xaminer nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume 1999 number(s), publisher, city and/or country where published.	T ²
		SANCHEZ-PRIETO, et al., "Lack of Correlation Between p53 Protein Level and Sensitivity to DNA-damaging Agents in Keratinocytes Carrying Adenovirus E1a Mutants," Oncogene, 11:675-682 (1995)	
		SAUTHOFF, et al., "Deletion of the Adenoviral E1b-19kD Gene Enhances Tumor Cell Killing of a Replicating Adenoviral Vector," Human Gene Therapy, 11:379-388 (February 10, 2000)	
		SAUTHOFF, et al., "p53 Expression Late in the Life Cycle of a Replication-competent Adenovirus Improves Tumor Cell Killing and Deletion of the Death Protein Improves Specificity," Proceedings of the American Association for Cencer Research, 43:1098, abstract No. 5439 (March 2002)	
		SCHWARZ, et al., "Interactions of the p107 and Rb Proteins with E2F During the Cell Proliferation Response," The EMBO Journal, 12(3):1013-1020 (1993)	
		SELLERS, et al., "A Potent Transrepression Domain in the Retinoblastoma Protein Induces a Cell Cycle Arrest When Bound to EZF Sites," Proc. Natl. Acad. Sci. USA, 92:11544-11548 (December 1995)	_
		SHAY, et al., "A Survey of Telomerase Activity in Human Cancer," European Journal of Cancer, 33(5):787-791 (1997)	
		SHAY, et al., "Telomerase and Cancer," Human Molecular Genetics, 10(7):677-685 (April 2001)	
	1	SHI, et al., "Modulation of the Specificity and Activity of a Cellular Promoter in an Adenoviral Vector," Human Gene Therapy, 8:403-410 (March 1, 1997)	
		STEINWAEDER, et al., "Insulation from Viral Transcriptional Regulatory Elements Improves Inducible Transgene Expression from Adenovirus Vectors in Vitro and In Vivo," Gene Therapy, 7(7):555-567 (April 2009).	
		STEWART, D., "Oncolytic Adenovirus Dependent on Two Prevalent Alterations in Human Cancer, oral presentiation presented at the Eleventh International Conference on Gene Therapy of Cancer, San Diego, CA, December 12-14, 2002	

	Cull Blogget 4. (
		Date	
Examiner			l 1
		Considered	
Signature	W MOCO 60	Drow line through o	itation if not in conformance and not

Signature | CHAMBER | Intelligence considered, whether or not classion is in conformance with MPEP 600, There is through classion if no in conformance and not considered, include copy of this form with next communication to applicate.

1 Applicant's insignature classified despitation in marker (potions). A population is a passe a check met here if English insignage Translation is attained.

1 Applicant's insignature classified despitation in marker (potions). A population is to passe a check met here if English insignage Translation is attained.

1 Applicant's insignature classified despitation in marker (potions). A population is a passe a check met here if English insignage Translation is attained.

1 Applicant's insignature classified in the second of the control of the intervent of the check of the control of the co Commissioner for Patents, Washington, DC 20231.

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Constitute for form 1449/PTO			(di 1990, no persona ca-	Complete if Known			
Set Stitute for form 1449/PTO				Application Number	10/081,961		
INFO	ORMATION	DIS	CLOSURE	Filing Date	February 22, 2002	- 00-	
STATEMENT BY APPLICANT				First Named Inventor	Gorziglia	UFCE!	VER
				Art Unit	1653	- Man	VEL
i	(Use as many she	ets as n	ecessary)	Examiner Name		MAY 082	00.7
Sheet	21	of	23	Attorney Docket Number	4-31890A	FECH CENTER	-0
	21					- OLIVIER 100	10 /-

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	AL LETTERS), title of the article (when appropriate), title of rial, symposium, catalog, etc.), date, page(s), volume-issue er, city and/or country where published.			
		STEWART, et al., "OAV001, an Oncolytic Adenovirus Dependent on Rb-Pathway Alterations in Human Cancer," American Society for Gene Therapy, 5th Annual Meeting, June 5-9, 2002; oral presentation presented June 7, 2002				
		STEWART, et al., "OAV001, an Oncolytic Adenovirus Dependent on Rb-Pathway Alterations in Human Cancer," Molecular Therapy, 5(5):abstract No. 53 (May 2002)				
		STEWART, et al., "Telomerase and Human Tumorigenesis," Seminars in Cancer Biology, 10:399-406 (December 2000)				
		STRAUSS, et al., "Unrestricted Cell Cycling and Cancer," Nature Medicine, 1(12):1245-1246 (December 1995)				
		TAKAHASHI, et al., "Analysis of Promoter Binding by the E2F and pRB Families In Vivo: Distinct E2F Proteins Mediate Activation and Repression," Genes & Development, 14:804-816 (April 1, 2000)				
		TAKAKURA, et al., "Cloning of Human Telomerase Catalytic Subunit (HTERT) Gene Promoter and Identification of Proximal Core Promoter Sequences Essential for Transcriptional Activation in Immortalized and Cancer Cells," Cancer Research, 53:551-557 (February 1, 1999)				
		TERHUNE, et al., "Regulation of Human Papillomavirus Type 31 Polyadenylation During the Differentiation-Dependent Life Cycle," Journal of Virology, 73(9):7185-7192 (September 1999)				
	T	TEVOSIAN, et al., "Expression of the E2F-1/DP-1 Transcription Factor in Murine Development," Cell Growth and Differentiation, 7:43-52 (January 1996)				
		TOLLEFSON, et al., "The Adenovirus Death Protein (E3-11.6K) is Required at Very Late Stages of Infection for Efficient Cell Lysis and Release of Adenovirus from Infected Cells," Journal of Virology, 70(4):2296-2308 (April 1996)				
		TSUKUDA, et al., "An E2F-responsive Replication-selective Adenovirus Targeted to the Defective Cell Cycle in Cancer Cells: Potent Antitumoral Efficacy but No Toxicity to Normal Cells," Cancer Research, 62:3438-3447 (June 15, 2022).				

Examiner	Date	
Signature	Considered	
Signature	the containing of the conformance with MPEP 609. Draw line through citation if not in conformance	e and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

consistent, include copy of this form with next communication to explication.

Applicants ruing existent designation number (episona). 2 Applicant is to place a check mark here if English injurged Transplants (explication of the Copy Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE unless it contains a valid OMB control number.

			OF 1980, NO persons us	e required to respond to a concession	Complete if Known		
Substitut	1449/PTO			Application Number	10/081,961		
INFO	RMATION	DIS	CLOSURE	Filing Date	February 22, 2002	RECE	VER
STATEMENT BY APPLICANT					Gorziglia		
				Art Unit	1653	MAY 0 8 2	003
	(Use as many sh	eets as n	ecessary)	Examiner Name			
Sheet	22	of	23	Attorney Docket Number	4-31890A	TECH CENTER 18	00/29ni
<u> </u>		_					-/

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		VASSAUX, et al., "Insulation of a Conditionally Expressed Transgene in an Adenoviral Vector," Gene Therapy, 6:1192-1197 (1999)	
		VILE, et al., "The Oncolytic Virotherapy Treatment Platform for Cancer: Unique Biological and Biosafety Points to Consider," Cancer Gene Therapy, 9:1062-1067 (December 2002)	
		WAEHLER, et al., "Experimental Gene Therapy of Hepatocellular Carcinoma: Expression of IL-12, 4-19BL and IL-2 From a Single Adenoviral Vector," Abstract No. P33, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibbes, France, October 13-16, 2002	
		WAHLE, et al., "The Mechanism of 3' Cleavage and Polyadenylation of Eukaryotic Pre-MmA," Progress in Nucleic Acid Research and Molecular Biology, 57:41-71 (1997)	
		WEINBERG, R., "The Retinoblastoma Protein and Cell Cycle Control," Cell, 81:323-330 (May 5, 1995)	
		WEN, et al., "Effect of Viral Replication on Pharmacokinetics of 01/PEME, a Recombinant Oncolytic Adenovirus, in a Human Lung Cancer Aheograft Model," Proceedings of the American Association for Cancer Research, 43:1088, abstract No 5440 (March 2002)	
		WOLD, et al., "Adenovirus Proteins that Subvert Host Defenses," Trends in Microbiology, 2(11):437-443 (November 1994)	
		WOLD, et al., "Immune Responses to Adenoviruses: Viral Evasion Mechanisms and Their Implications for the Clinic," Current Opinion in Immunology, 11:380-386 (1999)	
		YU, et al., "Identification of the Transcriptional Regulatory Sequences of Human Kallikrein 2 and Their Use in the Construction of Calydon Virus 764, an Attenuated Replication Competent Adenovirus for Prostate Cancer Therapy, Cancer Research, §9.1498-1504 (April 1, 1999)	
		YU, et al., "The Addition of Adenovirus Type 5 Region E3 Enables Calydon Virus 787 to Eliminate Distant Prostate Tumor Xenografts," Cancer Research, 59:4200-4203 (September 1, 1999)	

Examiner	Date
	Considered
Signature	the part of the second and and

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation is not in conformance with MPEP 609. Draw line through citation is not include the citation in conformance with MPEP 609. Draw line through citation is not include the citation in conformance with MPEP 609. Draw line through citation is not include the citation in citati

consistent, include copy of this form with read communication to applicant.

A popilizar's using existing equilibrium control probability of popility and probability of the probability Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

he Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless is contains a valid OMB control number.

Complete if Known RECEIVED Application Number 10/081,961 INFORMATION DISCLOSURE Filing Date February 22, 2002 MAY 0 8 1003 STATEMENT BY APPLICANT First Named Inventor Gorziglia Art Unit 1653 TECH CENTER 1600/2900 (Use as many sheets as necessary) Examiner Name Attorney Docket Number 4-31890A Sheet 23 of 23

		NON PATENT LITERATURE DOCUMENTS	
xaminer nitials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ZHOU, et al., "E1A Sensitizes HER2/neu-overexpressing Ewing's Sarcoma Ceils to Topolsomerase II-targeting Anticancer Drugs," Cancer Research, 61:3394-3398 (April 15, 2001)	
		ZHU, et al., "In Vivo Spread of Oncolytic Adenoviruses in Xenograft Tumor Models," Molecular Therapy, 5(5):abstract No. 317 (May 2002)	
		ZSENGELLER, et al., "Adenovirus-Mediated Granulocyte-Macrophage Colony-Stimulating Factor Improves Lung Pathodgy of Putnonary Alvedar Proteinosis in Granulocyte-Macrophage Colony-Stimulating Factor-Deficient Mice." Human Gene Therapy, 25/101-2103 (September 20, 1998)	
		ZWICKER, et al., "Cell Cycle-regulated Transcription in Mammalian Cells," Progress in Cell Cycle Research, 1:91-99 (1995)	
		DONG, et al., "Angiostatin-Mediated Suppression of Cancer Metastases by Primary Neoplasms Engineered to Produce Granulocyte/Macrophage Colony-Stimulating Factor," J. Exp. Med., 188(4):755-75 (August 17, 1998)	

		٦
Examiner	Date	١
Signature	Considered	П
Olgitulature		-

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USF. 122 and 37 CFR 11.4. This collection is estimated to last incompanies including to process) an application. Confidentiality is governed by 35 USF. 1.22 and 37 CFR 11.4. This collection is estimated to last process and application from to the USPTO. There will not provide to complete incompanies not the gathering, proparing, and automating the complete application from the USPTO. There will not obtain the USPTO of the USPTO. The unit not obtained to the USPTO of the